FDA-Mandated CAR-T Monitoring Period Could Be Halved
July 25, 2024
July 25, 2024
WASHINGTON, July 25 (TNSres) -- The American Society of Hematology issued the following news release:
* * *
CAR-T toxicities are rare after two weeks in diffuse large B-cell non-Hodgkin lymphoma treatment, and shorter restriction periods could increase overall treatment accessibility
* * *
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely . . .
* * *
CAR-T toxicities are rare after two weeks in diffuse large B-cell non-Hodgkin lymphoma treatment, and shorter restriction periods could increase overall treatment accessibility
* * *
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely . . .